Adalben

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adalben

Property Description
Active Ingredient Albendazole (INN)
Form Oral Tablet
Pharmacological Class Anthelmintic
Common Use Treating parasitic worm infections
Origin Synthetic small molecule

What Type of Medicine is Adalben? (Definition and Classification)

Adalben is a brand-name prescription medication whose single active component is the generic substance, Albendazole, which belongs to the class of anti-parasitic drugs. Albendazole is formally classified as an anthelmintic, a specific type of medication used to target and eliminate parasitic worm infections, or helminths.

This medicine is a synthetic compound and a member of the benzimidazole family, a chemical structure that has been clinically recognized for its broad effectiveness against various parasitic species, including tapeworms and roundworms. Albendazole is included on the Model List of Essential Medicines, confirming its importance as a core component of health systems globally. This anthelmintic provides a targeted approach that is distinct from broad-spectrum drugs like general antibiotics.


What is Adalben Made Of and How is it Given? (Composition, Form, and Origin)

Adalben is provided as an oral tablet designed for swallowing, delivering the active ingredient Albendazole directly via the mouth. Albendazole is a synthetic small molecule, meaning it is entirely manufactured chemically and is not derived from a natural plant or microbial source.

As a single-entity drug, its therapeutic effect is based exclusively on the action of Albendazole, rather than a combination of different drugs. Adalben tablets are typically prescription-only (Rx) and are often used when specific tissue infections are confirmed. Once ingested, the drug works by effectively starving the parasitic worms of the necessary nutrients. Albendazole quickly absorbs into the body after administration. This rapid absorption is crucial because it allows the medicine to circulate efficiently and reach parasitic infections outside of the intestines. This mechanism is key to its general purpose: to deprive the worms of the energy they need and ultimately clear the parasitic infestation from the body.

Regulatory References

  1. WHO Essential Medicines List
  2. MedlinePlus, NIH - Albendazole Absorption

What side effects are possible with Adalben?

Possible Side Effects and Safety Information for Adalben

Adalben (albendazole) is associated with adverse reactions primarily affecting the liver and blood system. Frequencies of adverse reactions are typically classified according to regulatory standards (e.g., ICH frequency bands).

Very Common adverse reactions (ge 10%) reported in clinical trials include elevated liver enzymes and headache. Common reactions (1% to 10%) include abdominal pain, nausea, vomiting, dizziness, fever, and reversible alopecia (hair thinning).


Serious and Clinically Significant Adverse Reactions

Regulatory documents emphasize the risk of severe hepatotoxicity, including reports of acute liver failure, and severe hematologic toxicity, which includes fatal cases of bone marrow suppression leading to pancytopenia, agranulocytosis, and leukopenia. Monitoring of liver function tests (LFTs) and Complete Blood Counts (CBCs) is mandatory at the beginning of each 28-day cycle and every two weeks during therapy due to these risks. Treatment should be discontinued if clinically significant decreases in blood counts or liver enzyme elevations occur.

Neurological symptoms, such as seizures and raised intracranial pressure, may occur in patients treated for neurocysticercosis, often due to an inflammatory response from parasite death. Severe cutaneous reactions, including Stevens-Johnson syndrome, have also been reported postmarketing.


Population-Specific Safety Considerations and Restrictions

Adalben may cause embryo-fetal harm; therefore, it is contraindicated in pregnancy and for females of reproductive potential unless appropriate precautions are taken. Negative pregnancy testing is required prior to starting therapy, and effective non-hormonal contraception must be used during and for a specified period (e.g., three days) after treatment. Caution and more frequent monitoring are warranted for patients with pre-existing liver disease, as they may be at an increased risk for bone marrow suppression and hepatotoxicity.

Overdose and Emergency Response

Overdose and when to seek help

The following information is strictly based on official government regulatory documents detailing the potential manifestations and required emergency actions for Adalben (Albendazole) overexposure.

Overdose Scope

Category Official Regulatory Statement
Documented Overdose Presentations Acute overexposure may be associated with transient, nonspecific symptoms affecting the gastrointestinal tract and central nervous system. These include nausea, vomiting, abdominal pain, diarrhea, and somnolence (drowsiness).
Physiological Systems Affected Gastrointestinal and central nervous systems are the primary systems associated with acute manifestations documented in regulatory sources.
Emergency-response Statements Management for overexposure is limited to symptomatic and general supportive treatment. Procedures such as gastric lavage or administration of activated charcoal may be considered for recent ingestion.
When Immediate Medical Help Is Required Immediate medical attention must be sought for any suspected overdose or ingestion exceeding the prescribed dose. Regulatory guidance also instructs contacting a Poison Control Center immediately.

Overdose Classifications (High-Level)

Category Official Regulatory Statement
Antidote Information No specific antidote is known for Albendazole overexposure.
Monitoring Requirements Intensive medical monitoring or hospital observation may be required following a suspected overdose.

Connection to the Overall Overdose Profile

The regulatory documents establish that due to the lack of a known specific antidote, the primary response to overexposure is to seek immediate medical attention and initiate supportive care. This profile dictates that management focuses on alleviating the documented transient symptoms and monitoring for clinical stability.

Therapeutic Uses of Adalben

What Adalben Treats: Main Uses and Benefits

The therapeutic use of Adalben (Albendazole) centers on addressing parasitic worm infestations (helminthiasis), providing essential support for symptoms caused by both widespread intestinal infections and severe, tissue-invasive disease. The medication is primarily used to help with infections caused by parasitic worms.

It is commonly used to address conditions like neurocysticercosis and cystic hydatid disease involving organs such as the brain, liver, and lungs, as well as high-burden intestinal infestations including those caused by roundworms, hookworms, and whipworms.

In severe cases, Adalben provides support for addressing the parasitic presence, which may assist with easing pronounced neurological symptoms that interfere with daily functioning like seizures. In situations involving chronic infection, it is relevant for easing associated symptoms related to systemic imbalance, such as those associated with anemia and malnutrition.

“The medication assists with managing the heightened systemic burden of parasites, contributing to easing the overall symptom load during symptomatic periods.”


Quick Fact: Relief for Parasitic Symptoms
Symptom Cluster: Supports the easing of symptoms related to increased neurological activity and physical discomfort associated with addressing the parasitic presence and intestinal worms.
Clinical Context: Commonly used for conditions marked by severe systemic symptoms or high parasitic burden where functional stability is affected.

Regulatory References

  1. NIH MedlinePlus Drug Information on Albendazole

Eligibility and Restrictions for Use

Eligibility Scope for Adalben (Albendazole)

Adalben (Albendazole) is an anthelmintic medication whose use is strictly governed by regulatory eligibility rules concerning patient status and pre-existing conditions.


Eligibility Classification Population Group/Condition
Contraindicated Pregnancy and women thought to be pregnant; patients with a known hypersensitivity to Albendazole or other benzimidazole class compounds.
Conditional Use/Monitoring Required Patients with active liver disease or dysfunction; patients with pre-existing bone marrow suppression; patients being treated for neurocysticercosis who must be examined for retinal lesions.
Age-Related Rules Approved for use in adults and children ge 2 years for intestinal infections. Use in children under 1 year is generally not recommended or is contraindicated due to insufficient data.
Physiological Status Lactation (breastfeeding) is generally not recommended, and a specified period of contraception is required for females of reproductive potential during and after treatment.

Connection to the overall eligibility profile: The regulatory documents establish strict absolute contraindications based on allergy and pregnancy, which immediately prohibit the drug's use. For all other populations, the profile mandates conditional use, requiring routine monitoring of liver enzymes and blood counts due to the potential for hepatotoxicity and bone marrow suppression. These rules ensure that treatment aligns with the officially documented safety profile, including age-appropriate use and precautions for specific comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation details specific pharmacokinetic interactions for Adalben (Albendazole) that alter the systemic exposure of its active metabolite, Albendazole sulfoxide.

Documented Interaction Patterns

Co-administration with certain medicines may decrease the active metabolite’s concentration. Substances documented to lower plasma levels of Albendazole sulfoxide include Phenytoin, Carbamazepine, Phenobarbital, and Ritonavir. Conversely, other co-administered substances are documented to increase exposure. These include Dexamethasone, which increases the active metabolite’s AUC by approximately 56%, and Praziquantel, which increases C max and AUC by about 50%.

Adalben is documented to be an inducer of cytochrome P450 1A (CYP1A), which is relevant for the plasma concentrations of co-administered drugs like Theophylline.

Food and Substance Interactions

Adalben has a critical drug-food interaction: co-administration with a fatty meal is officially documented to significantly enhance the drug’s systemic exposure and bioavailability. This interaction is required to achieve necessary plasma concentrations. Grapefruit juice is also noted to increase the plasma levels of Albendazole. For patients with hepatic impairment, the drug's extensive liver metabolism is expected to significantly affect the pharmacokinetics of Albendazole sulfoxide, a specific population-dependent interaction note.

Mechanism of Action

Microtubule Disruption and Structural Failure

This domain covers the drug's primary action: binding to the beta-tubulin protein, which is vital for building internal microtubules within the target organism's cells. This binding acts as a polymerization inhibitor, rapidly causing the collapse of the cell's structural scaffolding and transport system, which is the initial step toward the drug's overall effect.


Impairment of Energy Metabolism

The resulting structural damage severely compromises the target organism's ability to absorb essential nutrients, particularly glucose. This blockade of nutrient uptake and utilization initiates a mechanistic cascade leading to a profound depletion of cellular energy (ATP), which is necessary for the organism's survival and function. This metabolic failure impairs the parasitic activity and leads to physiological adjustments that contribute to the drug's observed biological effect.

Dosage and Administration Information

How to Use Adalben

Adalben (Albendazole) is designated solely for the oral route of administration. A mandatory condition for use is that the tablets must be taken with food to ensure sufficient absorption, with optimal bioavailability occurring when consumed alongside a fatty meal. The tablets are designed to be practical, permitting them to be chewed, crushed, or swallowed whole with water.

The dosing schedule is structured primarily by infection type and patient weight. For invasive tissue infections, the regimen requires twice daily (BID) administration. The official dose is 400 mg per dose for individuals weighing 60 kg or more. For patients weighing less than 60 kg, the dose is adjusted to 15 mg/kg/day, and the total daily dose must not exceed 800 mg.

The duration of use is strictly defined by the condition being addressed. Neurocysticercosis is treated for 8 to 30 days. Hydatid disease requires a cyclic approach, consisting of three 28-day courses separated by 14-day intervals. Shorter courses, such as a single dose, are utilized for common intestinal parasites.

Recent Clinical Evidence

Adalben: Recent Clinical Evidence

Evidence for Use in Neurocysticercosis (NCC)

Research has explored the use of Adalben for Neurocysticercosis (NCC), a condition involving cysts in the brain, using randomized controlled trials (RCTs). These studies primarily monitored outcomes related to the disappearance or regression of active cysts visualized on neuroimaging and tracked changes in seizure frequency. Findings were mixed regarding patterns observed in seizure control, and certainty remains low for the long-term impact on neurological outcomes years after the cysts appear inactive.

Evidence for Use in Cystic Hydatid Disease

Research has examined Adalben for use in Cystic Hydatid Disease (parasitic cysts in organs like the liver and lungs), often alongside surgical procedures. Studies evaluated outcomes related to cyst viability and changes in cyst size or volume. Research describes patterns related to measurements of cyst inactivation and reported rates of recurrence in the observed populations. However, comparative evidence is lacking regarding the optimal duration or use of different combination regimens, and older studies varied widely in their definition of successful outcomes.

Evidence for Use in Soil-Transmitted Helminth Infections

The research regimen was extensively studied for common intestinal parasites like roundworm and hookworm in children from endemic regions. Research describes favorable cure and egg reduction measurements against these parasites. Conversely, when applied as a single-dose regimen, the evidence suggests findings were mixed, reporting variable and lower measurements of parasitic clearance against the whipworm (T. trichiura).

Research Gaps and Follow-up Limitations

Across all indications, follow-up durations were limited, focusing mainly on immediate changes rather than long-term functional status. The research regimen was studied in children for soil-transmitted infections, but data for complex groups, such as older adults with comorbidities, remain insufficient. Overall, the evidence highlights where research is well-established and where persistent uncertainty exists, such as the effectiveness against whipworm and the long-term durability of the effects.

Key Studies & References

  1. Short course of albendazole therapy for neurocysticercosis: A prospective randomized trial comparing
  2. The efficacy and safety of three 30-day courses of albendazole in patients with neurocysticercosis
  3. Albendazole versus Praziquantel in the Treatment of Neurocysticercosis: A Meta-analysis of Comparative Trials
  4. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials
  5. Drug Treatment of Hydatid Cyst With Albendazole and Praziquantel in Humans
  6. Soil-transmitted helminthiases - World Health Organization (WHO) Fact Sheet/Data

Frequently Asked Questions (FAQ)

Common questions about Adalben (FAQ)


Q: How long does the effect of Adalben last?

Adalben (Albendazole) is rapidly processed by the body into its active component. Official regulatory information reports that the half-life—the time it takes for half of the active substance to leave the body—is about 8.5 hours in most individuals. This reported half-life is a factor considered when establishing the approved dosing schedules for certain conditions.


Q: Does Adalben cause drowsiness?

Regulatory documents indicate that headache and dizziness are reported as common side effects. Somnolence (drowsiness) is reported in official post-marketing settings, though it is not classified among the more commonly occurring adverse reactions in clinical trials.


Q: What should I do if I feel dizzy after taking Adalben?

Official patient materials describe dizziness as a potential side effect of the medicine. If dizziness or other concerning effects occur, official information directs individuals to seek guidance from a healthcare provider regarding their treatment plan.


Q: What are the signs of a severe allergic reaction to Adalben?

Severe hypersensitivity reactions are documented in official documents and can include signs such as an unexpected rash, itching, or swelling of the face, tongue, or throat. Rare, very serious skin reactions, such as Stevens-Johnson syndrome, have also been reported.


Q: Can Adalben affect my ability to drive or operate machinery?

Because the drug can cause side effects like dizziness, official documentation advises caution for those who drive or operate heavy machinery. If dizziness or similar effects occur, official patient counseling information advises against driving or operating machinery.


Q: What types of side effects are generally mild with Adalben?

Official documents classify adverse reactions by how often they occur. Side effects reported as very common or common in studies, such as headache, abdominal pain, nausea, and reversible hair thinning (alopecia), are considered less severe than the serious hematologic and hepatic risks outlined in official warnings.


Q: What happens if I miss a dose of Adalben?

Official patient prescribing information generally recommends that an individual take the missed dose as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the recommendation is to skip the missed dose entirely and continue with the regular schedule. Official guidance generally advises against taking a double dose.


Q: Is Adalben similar to other medications I might have heard of?

Adalben is the brand name for albendazole, which belongs to the benzimidazole class of anthelmintic drugs. Other medicines that share this classification and a similar basic mechanism of action include Mebendazole, as noted in medical literature and official classifications.


Q: Why do people sometimes stop taking Adalben?

Treatment with this medication may be stopped if certain serious side effects develop. Official regulatory warnings state that treatment should be discontinued if mandatory monitoring reveals a significant decrease in blood cell counts or a significant elevation of liver enzymes.


Q: Can children or teenagers use Adalben?

Official documents confirm the drug is approved for use in adults and children ge 2 years old for specific parasitic infections. Use in children under 1 year is generally not authorized or is contraindicated by official documents due to insufficient safety and effectiveness data.


Q: Is Adalben considered a new drug?

Adalben (Albendazole) is not considered a new medication. The drug was first approved by the U.S. Food and Drug Administration (FDA) for specific indications in June 1996.


Q: Is there a generic version of Adalben available?

Yes, Adalben is the brand name for the generic substance albendazole. Generic versions of albendazole are widely available under various names and contain the same active ingredient as the brand-name product.


Q: Are there certain foods or drinks I should avoid while using Adalben?

Regulatory documents identify an interaction with grapefruit. Documents note that consuming grapefruit or grapefruit juice can increase the concentration of the active drug component in the bloodstream.


Q: How long do most people stay on Adalben?

The treatment length varies significantly and is determined by the specific type of parasitic infection being treated. Courses can range from a single dose for common intestinal worms up to multiple, repeated 28-day cycles for complex tissue infections like hydatid disease.


Q: Can Adalben affect laboratory blood test results?

The drug is associated with changes that are measured by lab tests, including potential changes to liver enzyme levels and a decrease in certain blood cell counts. Due to these documented effects, official regulatory guidelines require routine monitoring of liver function tests and blood counts during treatment.


Q: Does Adalben have a Black Box Warning?

The U.S. FDA label for the brand-name drug Adalben does not contain a Boxed Warning (often called a Black Box Warning). However, the label does include serious warnings about the risk of liver damage (hepatotoxicity) and severe blood disorders (bone marrow suppression).


Q: What happens if I accidentally take too much Adalben?

Official information regarding overdose notes the potential for symptoms such as elevated liver enzymes, headaches, and fever. Official guidance states that immediate medical attention should be sought if an overdose is suspected.


Q: Is Adalben habit-forming or addictive?

Adalben is not classified as a controlled substance by regulatory bodies. Official documents do not include information suggesting the medication has the potential for abuse, physical dependence, or addiction.


Q: Does Adalben interact with any over-the-counter cold medicines?

Specific interactions with all over-the-counter cold medicine ingredients are not universally listed in official documents. Official information suggests caution when the drug is taken alongside other medications that are also metabolized by the liver, such as certain components found in cold remedies.


Q: Does taking Adalben at a specific time of day matter?

For twice-daily dosing regimens, the most important administration factor is taking the medicine with food to maximize absorption. Official guidance emphasizes that taking the doses at the same time(s) each day supports maintaining a consistent level of the drug in the bloodstream.


Q: How does Adalben differ from other drugs in its class?

Adalben (Albendazole) shares its core mechanism with other benzimidazole drugs, such as Mebendazole. However, its approved use is often differentiated by its specific efficacy in treating tissue infections like Neurocysticercosis and Cystic Hydatid Disease, which are key approved indications highlighted in regulatory information.


Q: Can Adalben be used by people with kidney issues?

Regulatory documents indicate that there is generally no requirement for a dose adjustment for patients who have renal (kidney) impairment.

How should Adalben be stored and disposed of?

How to Store and Dispose of Adalben

Adalben (dexmedetomidine) is subject to specific regulatory storage and disposal requirements to ensure its stability and safety. The unopened vials must be stored at controlled room temperature, typically between 20 C to 25 C, and protected from light. It is essential to avoid freezing the product.

Storage Condition Requirement
Temperature (Unopened) 20 C to 25 C
Light Protection Required
Handling Precaution Do not freeze

Before administration, the solution must be visually inspected, and if particulate matter or discoloration is observed, it must be discarded. Once diluted for intravenous use, the solution is stable for a maximum of 24 hours whether stored at room temperature or refrigerated. Any unused portion of the vial, along with expired stock and remaining diluted solution, must be properly disposed of following the official institutional protocols for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adalben found in:

A-Z Index: